Sugi Predict

Sugi Predict / Compounds / SCHEMBL2551365

SCHEMBL2551365

SCHEMBL2551365

O=C(O)CC1COCCN1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ITGB3 P05106 1/20 0.39
▸ ITGB2 P05107 1/20 0.39
▸ ITGB1 P05556 1/20 0.39
▸ ITGAV P06756 1/20 0.39
▸ ITGA2B P08514 1/20 0.39
▸ ITGA5 P08648 1/20 0.39
▸ ITGB5 P18084 1/20 0.39
▸ ITGAL P20701 1/20 0.39
▸ ARG1 P05089 2/20 0.37
▸ SLC6A12 P48065 6/20 0.36
▸ SLC6A11 P48066 6/20 0.36
▸ SLC6A13 Q9NSD5 5/20 0.36
▸ SLC6A1 P30531 4/20 0.36
▸ GABRA5 P31644 4/20 0.36
▸ GABRB2 P47870 4/20 0.36
▸ GABRA1 P14867 3/20 0.36
▸ GABRR1 P24046 3/20 0.36
▸ GABRA4 P48169 3/20 0.36
▸ MALT1 Q9UDY8 1/20 0.32
▸ MAP4K1 Q92918 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29957155 1.00 ITGB3 (0.39) ITGB3ITGB2ITGB1ITGAVITGA2B
SCHEMBL26267274 1.00 ITGB3 (0.39) ITGB3ITGB2ITGB1ITGAVITGA2B
Hydrochloric Acid SCHEMBL15572261 0.98 ITGB3 (0.38) ITGB3ITGB2ITGB1ITGAVITGA2B
SCHEMBL27276448 0.82 IRAK4 (0.37) ARG1MALT1MAP4K1IRAK4
SCHEMBL2920617 0.82 IRAK4 (0.37) ARG1MALT1MAP4K1IRAK4
SCHEMBL2380660 0.81 ARG1 (0.33) ARG1MALT1MAP4K1IRAK4
SCHEMBL4666386 0.81 ARG1 (0.38) ARG1MALT1
SCHEMBL16771700 0.81 ARG1 (0.38) ARG1MALT1
SCHEMBL16771693 0.81 ARG1 (0.38) ARG1MALT1
SCHEMBL31017525 0.80 MALT1 (0.38) ITGB1ITGA5ARG1MALT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112424194-B Immunomodulator, composition and preparation method thereof 贝达药业股份有限公司 2024-02-06 — — CN claimed
CN-112424194-B Immunomodulator, composition and preparation method thereof 贝达药业股份有限公司 2024-02-06 — — CN disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 — — US disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 — — US disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 — — US disclosed
EP-3390404-B1 TRICYCLIC COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS NOVARTIS AG (CH) 2021-07-21 — — EP disclosed
US-10377770-B2 Tricyclic compounds and compositions as kinase inhibitors NOVARTIS AG (CH) 2019-08-13 — — US disclosed
US-20180362542-A1 TRICYCLIC COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2018-12-20 — — US disclosed
EP-3390404-A1 TRICYCLIC COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS Novartis AG (CH) 2018-10-24 — — EP disclosed
EP-2888241-B1 2,4,5,6-Substituted 3,6-dihydropyrimidine derivatives as hepatitis B virus (HBV) polymerase inhibitors for the treatment of e.g. chronic hepatitis SUNSHINE LAKE PHARMA CO LTD (CN) 2017-07-12 — — EP disclosed
US-20060211097-A1 Process for producing enantiopure beta-amino acid derivatives, and enantiopure beta-amino acid derivatives SOLVAY S.A. (BE) 2006-09-21 — — US disclosed
US-20060189591-A1 Five-membered heterocyclic derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-08-24 — — US disclosed
US-20060128685-A1 Pyrazole derivative DAIICHI PHARMACEUTICAL CO., LTD., (JP) 2006-06-15 — — US disclosed
CN-1774435-A 5-membered heterocyclic derivative DAIICHI SEIYAKU CO (JP) 2006-05-17 — — CN disclosed
CN-1768149-A Process for producing enantiopure beta-amino acid derivatives, and enantiopure beta-amino acid derivatives SOLVAY (BE) 2006-05-03 — — CN disclosed
CN-1759110-A Pyrazole derivatives DAIICHI SEIYAKU CO (JP) 2006-04-12 — — CN disclosed
EP-1621537-A1 FIVE-MEMBERED HETEROCYCLIC DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-02-01 — — EP disclosed
EP-1613762-A2 PROCESS FOR PRODUCING ENANTIOPURE BETA-AMINO ACID DERIVATIVES, AND ENANTIOPURE BETA-AMINO ACID DERIVATIVES SOLVAY (Société Anonyme) (BE) 2006-01-11 — — EP disclosed
EP-1591443-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-02 — — EP disclosed
WO-2004087940-A2 PROCESS FOR PRODUCING ENANTIOPURE β-AMINO ACID DERIVATIVES, AND ENANTIOPURE β-AMINO ACID DERIVATIVES Solvay (Société Anonyme) (BE) 2004-10-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128685-A1 Pyrazole derivative PTGS1, PTGS2, PTGER1 ITGB3 1328/4885ITGB2 1975/4885ITGB1 2341/4885
US-11873291-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS ITGB3 4867/4885ITGB2 4860/4885ITGB1 4878/4885
US-20060189591-A1 Five-membered heterocyclic derivative PTGS1, PTGIS, PTGS2 ITGB3 2550/4885ITGB2 2621/4885ITGB1 2458/4885
US-20180362542-A1 TRICYCLIC COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS BRAF, RAF1, MAP3K1 ITGB3 4227/4885ITGB2 4411/4885ITGB1 4320/4885
US-10377770-B2 Tricyclic compounds and compositions as kinase inhibitors BRAF, RAF1, MAP3K1 ITGB3 4227/4885ITGB2 4411/4885ITGB1 4320/4885
US-20060211097-A1 Process for producing enantiopure beta-amino acid derivatives, and enantiopure beta-amino acid derivatives LPL, CEL, IL4I1 ITGB3 3928/4885ITGB2 4456/4885ITGB1 4674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.